Stockholders' Equity Attributable to Parent of Inozyme Pharma, Inc. from 31 Dec 2018 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
Summary
Inozyme Pharma, Inc. quarterly Stockholders' Equity Attributable to Parent in USD history and change rate from 31 Dec 2018 to 31 Mar 2025.
  • Inozyme Pharma, Inc. Stockholders' Equity Attributable to Parent for the quarter ending 31 Mar 2025 was $31,798,000, a 73% decline year-over-year.
Source SEC data
View on sec.gov
Stockholders' Equity Attributable to Parent, Quarterly (USD)
Stockholders' Equity Attributable to Parent, YoY Quarterly Change (%)

Inozyme Pharma, Inc. Quarterly Stockholders' Equity Attributable to Parent (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $31,798,000 -$87,038,000 -73% 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $57,826,000 -$82,653,000 -59% 31 Dec 2024 10-Q 14 May 2025 2025 Q1
Q3 2024 $82,788,000 -$77,425,000 -48% 30 Sep 2024 10-Q 05 Nov 2024 2024 Q3
Q2 2024 $94,420,000 -$11,173,000 -11% 30 Jun 2024 10-Q 05 Nov 2024 2024 Q3
Q1 2024 $118,836,000 +$15,489,000 +15% 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $140,479,000 +$22,085,000 +19% 31 Dec 2023 10-Q 14 May 2025 2025 Q1
Q3 2023 $160,213,000 +$25,433,000 +19% 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $105,593,000 -$43,583,000 -29% 30 Jun 2023 10-Q 05 Nov 2024 2024 Q3
Q1 2023 $103,347,000 +$9,118,000 +9.7% 31 Mar 2023 10-Q 05 Nov 2024 2024 Q3
Q4 2022 $118,394,000 +$9,126,000 +8.4% 31 Dec 2022 10-K 10 Mar 2025 2024 FY
Q3 2022 $134,780,000 +$8,806,000 +7% 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $149,176,000 +$10,902,000 +7.9% 30 Jun 2022 10-Q 07 Nov 2023 2023 Q3
Q1 2022 $94,229,000 -$54,660,000 -37% 31 Mar 2022 10-Q 07 Nov 2023 2023 Q3
Q4 2021 $109,268,000 -$48,835,000 -31% 31 Dec 2021 10-K 12 Mar 2024 2023 FY
Q3 2021 $125,974,000 -$41,942,000 -25% 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $138,274,000 +$188,293,000 30 Jun 2021 10-Q 10 Nov 2022 2022 Q3
Q1 2021 $148,889,000 +$189,689,000 31 Mar 2021 10-Q 10 Nov 2022 2022 Q3
Q4 2020 $158,103,000 +$191,322,000 31 Dec 2020 10-K 22 Mar 2023 2022 FY
Q3 2020 $167,916,000 +$194,711,000 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q2 2020 $50,019,000 -$27,125,000 -118% 30 Jun 2020 10-Q 09 Nov 2021 2021 Q3
Q1 2020 $40,800,000 -$22,031,000 -117% 31 Mar 2020 10-Q 09 Nov 2021 2021 Q3
Q4 2019 $33,219,000 -$19,344,000 -139% 31 Dec 2019 10-K 15 Mar 2022 2021 FY
Q3 2019 $26,795,000 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $22,894,000 30 Jun 2019 10-Q 12 Nov 2020 2020 Q3
Q1 2019 $18,769,000 31 Mar 2019 10-Q 12 Nov 2020 2020 Q3
Q4 2018 $13,875,000 31 Dec 2018 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.